Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Drug Digest: Development and Scalability of ADCs and CGTs

July 07, 2022

In this exclusive Drug Digest video, experts from Roche and MilliporeSigma divulge factors that could influence an organization to pursue specific biomolecules for development.

Formulating Biologics: A Learning Curve

July 03, 2022

Biologics are forming a greater proportion of the development pipeline, but there are still some formulation difficulties to overcome to ensure clinical and commercial success.

Innovations in Single-Cell Proteomics Drive Advances in Disease Research

July 03, 2022

Single-cell analytical technologies can deepen the understanding of cell biology and, therefore, disease mechanisms.

Challenges to Formulation Development for Highly Potent APIs

July 03, 2022

Lack of toxicity data and poor physicochemical properties must be overcome.

What is Wrong with the Neuroscience Drug Market?

July 02, 2022

Pharma should expand on successful cell therapies in oncology by applying these development and manufacturing methods to neuronal cell therapies.

Process Development Struggles with Molecular Diversity

July 02, 2022

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

How Can We Come Up Short So Often?

July 02, 2022

Systemic inefficiencies in the pharmaceutical industry undermine problem-solving efforts.

Inceptor Bio Collaborates with University of Minnesota to Develop Cell Therapy Platform

June 30, 2022

Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

June 27, 2022

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.

First Successful Efficacy Study Against Omicron With COVID-19 Vaccine

June 27, 2022

The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.